Research programme: hydrocodone immediate release - Ensysce Biosciences

Drug Profile

Research programme: hydrocodone immediate release - Ensysce Biosciences

Alternative Names: IR Hydrocodone - Ensysce Biosciences; IR Hydrocodone - PharmacoFore; IR Hydrocodone Bio-MD™ System; PF 6129

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 24 Feb 2016 Preclinical trials in Pain in USA (PO) before February 2016
  • 19 Jan 2016 Signature Therapeutics has merged into Ensysce Biosciences
  • 03 Sep 2012 PharmacoFore is now called Signature Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top